NCT03407768Completed
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer
Role of Individualized Intervention(s) on Quality of Life and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Early-Stage Breast Cancer
Source: ClinicalTrials.gov · Last updated 5 Dec 2024
Brief summary (registry, in English)
Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with more adverse effects and decline in quality of life (QOL). Various behavioral and complementary interventions can be effective in reducing treatment-related side effects. The study aims to evaluate if individually-tailored behavioral and complementary interventions could improve treatment tolerance and adherence in women with early stage breast cancer. This benefit will be assessed primarily by change in QOL and secondarily by adherence to adjuvant endocrine treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 41 (actual)
- First submitted
- 24 Oct 2017
- Start date
- 1 Jul 2018
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- University of Saskatchewan
- Diseases
- Childhood cancers
- NCT number
- NCT03407768
What you commit to
- Study type: Interventional
- Participants enrolled: 41
- From 1 Jul 2018 to the primary completion date, 30 Nov 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Women who are on single agent endocrine therapy
Other
- Post-menopausal women
Who the study is looking for
- Premenopausal women with histologically-proven, completely resected, hormone receptor-positive (defined as ER≥10% and/or PgR≥10%) stage 1, 2, and 3 invasive breast cancer who are treated with combination of anti-estrogen therapy (LHRH agonist and an aromatase inhibitor or tamoxifen)
Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Allan Blair Cancer Center Coordinator of this site? Confirm its status | Regina | Canada | Unknown status |
| Saskatoon Cancer Center Coordinator of this site? Confirm its status | Saskatoon | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.